12:00 AM
Nov 01, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

IW001: Phase I started

ImmuneWorks began an open-label, U.S. Phase I trial to evaluate once-daily 0.1, 0.5 and 1 mg doses of oral IW001 for 24 weeks in 30 patients. IW001 has...

Read the full 118 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >